Mr. Glenn Saldanha Chairman & and Managing Director, Glenmark Pharmaceuticals Limited, conferred 'India Pharma Leader Award' by the Government of India

Mr. Glenn Saldanha Chairman & and Managing Director, Glenmark Pharmaceuticals Limited, conferred ‘India Pharma Leader Award’ by the Government of India

Indian Ministry for Chemicals and Fertilizers on Thursday conferred 1st India Pharma awards to 12 Indian drug companies under various categories to motivate Indian Pharma and medical devices industries. 673 more words


Glenmark Pharmaceuticals entering $130M market with two new generic medicines

Glenmark Pharmaceuticals has been granted final approval by the US Food & Drug Administration for Potassium Chloride Extended-Release Capsules USP, 10 mEq, generic version of Actavis Laboratories’ equivalent drug. 107 more words


Glenmark's generic Multaq tablets wait for final FDA approval after tentative

Glenmark Pharmaceuticals Inc., has been granted tentative approval by the USFDA for its Dronedarone Tablets, 400 mg, the generic version Multaq Tablets, 400 mg of Sanofi-Aventis U.S. 138 more words


Glenmark confirms reaching agreement with Roche over patent disputes

The Indian Exchange had sought clarification from Glenmark Pharmaceuticals Limited with respect to recent news item captioned “Roche, Glenmark Settle Patent suit over cancer drug”. 86 more words


Glenmark's Linezolid, version of Pfizer's Zyvox, gets nod from FDA

Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Linezolid Tablets, 600 mg, the therapeutic equivalent of Zyvox Tablets, 600 mg of Pharmacia and Upjohn Company, a subsidiary of Pfizer, Inc. 75 more words




Phase III

A DP-IV inhibitor potentially for treatment of type II diabetes.

EMD-675992; GRC-8200

CAS No. 868771-57-7


Note………The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent… 152 more words

Design, Synthesis, and Pharmacological Evaluation of 5,6-Disubstituted Pyridin-2(1H)-one Derivatives as Phosphodiesterase 10A (PDE10A) Antagonists

We report the design and synthesis of novel 5,6-diarylated pyridin-2(1H)-one derivatives as pharmacophoric PDE10A inhibitors. This highly potent molecular scaffold was developed from an inactive diarylpyridine-2-amine derivative 3b by extensive and systematic analogue synthesis and SAR analysis. 268 more words

Abraham Thomas